Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer

Erik N. Taylor; Colin M. Wilson; Stefan Franco; Henning De May; Lorél Y. Medina; Yirong Yang; Erica B. Flores; Eric Bartee; Reed G. Selwyn; Rita E. Serda

doi:10.3390/ijms231810525

Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer

Erik N. Taylor, Colin M. Wilson, Stefan Franco, Henning De May, Lorél Y. Medina, Yirong Yang, Erica B. Flores, Eric Bartee, Reed G. Selwyn, Rita E. Serda

Research output: Contribution to journal › Article › peer-review

Abstract

Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities to overcome this challenge by refining tumor identification and monitoring therapeutic responses to cancer immunotherapy. In the current work, spatial and quantitative analysis of tumor burden were performed using simultaneous [¹⁸F]FDG-PET/MRI to monitor therapeutic responses to a novel silicified cancer cell immunotherapy in a mouse model of disseminated serous epithelial ovarian cancer. Tumor progression was validated by bioluminescence imaging of luciferase expressing tumor cells, flow cytometric analysis of immune cells in the tumor microenvironment, and histopathology. While PET demonstrated the presence of metabolically active cancer cells through [¹⁸F]FDG uptake, MRI confirmed cancer-related accumulation of ascites and tissue anatomy. This approach provides complementary information on disease status without a confounding signal from treatment-induced inflammation. This work provides a possible roadmap to facilitate accurate monitoring of therapeutic responses to cancer immunotherapies.

Original language	English (US)
Article number	10525
Journal	International journal of molecular sciences
Volume	23
Issue number	18
DOIs	https://doi.org/10.3390/ijms231810525
State	Published - Sep 2022

Keywords

MRI
PET
bioluminescence
cancer vaccine
cell silicification
fluorodeoxyglucose
immunotherapy

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms231810525

Cite this

Taylor, E. N., Wilson, C. M., Franco, S., De May, H., Medina, L. Y., Yang, Y., Flores, E. B., Bartee, E., Selwyn, R. G., & Serda, R. E. (2022). Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer. International journal of molecular sciences, 23(18), [10525]. https://doi.org/10.3390/ijms231810525

@article{7efa30ef197c4e9196ff9e8817443579,

title = "Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer",

abstract = "Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities to overcome this challenge by refining tumor identification and monitoring therapeutic responses to cancer immunotherapy. In the current work, spatial and quantitative analysis of tumor burden were performed using simultaneous [18F]FDG-PET/MRI to monitor therapeutic responses to a novel silicified cancer cell immunotherapy in a mouse model of disseminated serous epithelial ovarian cancer. Tumor progression was validated by bioluminescence imaging of luciferase expressing tumor cells, flow cytometric analysis of immune cells in the tumor microenvironment, and histopathology. While PET demonstrated the presence of metabolically active cancer cells through [18F]FDG uptake, MRI confirmed cancer-related accumulation of ascites and tissue anatomy. This approach provides complementary information on disease status without a confounding signal from treatment-induced inflammation. This work provides a possible roadmap to facilitate accurate monitoring of therapeutic responses to cancer immunotherapies.",

keywords = "MRI, PET, bioluminescence, cancer vaccine, cell silicification, fluorodeoxyglucose, immunotherapy",

author = "Taylor, {Erik N.} and Wilson, {Colin M.} and Stefan Franco and {De May}, Henning and Medina, {Lor{\'e}l Y.} and Yirong Yang and Flores, {Erica B.} and Eric Bartee and Selwyn, {Reed G.} and Serda, {Rita E.}",

note = "Funding Information: UNM Comprehensive Cancer Center Shared Resources were supported by a National Institute of Health grant NCI 2P30 CA118100 (C.M.W.). This work was also supported by UNM Brain & Behavioral Health Institute Mini-Grant #2019-20-002 (R.E.S.) and UNM Faculty Start-up funding (R.E.S. and E.N.T.). We thank the Preclinical Imaging Core for support by NIH S10OD021598-01 (R.G.S.). Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/ijms231810525",

language = "English (US)",

volume = "23",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "18",

}

TY - JOUR

T1 - Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer

AU - Taylor, Erik N.

AU - Wilson, Colin M.

AU - Franco, Stefan

AU - De May, Henning

AU - Medina, Lorél Y.

AU - Yang, Yirong

AU - Flores, Erica B.

AU - Bartee, Eric

AU - Selwyn, Reed G.

AU - Serda, Rita E.

N1 - Funding Information: UNM Comprehensive Cancer Center Shared Resources were supported by a National Institute of Health grant NCI 2P30 CA118100 (C.M.W.). This work was also supported by UNM Brain & Behavioral Health Institute Mini-Grant #2019-20-002 (R.E.S.) and UNM Faculty Start-up funding (R.E.S. and E.N.T.). We thank the Preclinical Imaging Core for support by NIH S10OD021598-01 (R.G.S.). Publisher Copyright: © 2022 by the authors.

PY - 2022/9

Y1 - 2022/9

N2 - Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities to overcome this challenge by refining tumor identification and monitoring therapeutic responses to cancer immunotherapy. In the current work, spatial and quantitative analysis of tumor burden were performed using simultaneous [18F]FDG-PET/MRI to monitor therapeutic responses to a novel silicified cancer cell immunotherapy in a mouse model of disseminated serous epithelial ovarian cancer. Tumor progression was validated by bioluminescence imaging of luciferase expressing tumor cells, flow cytometric analysis of immune cells in the tumor microenvironment, and histopathology. While PET demonstrated the presence of metabolically active cancer cells through [18F]FDG uptake, MRI confirmed cancer-related accumulation of ascites and tissue anatomy. This approach provides complementary information on disease status without a confounding signal from treatment-induced inflammation. This work provides a possible roadmap to facilitate accurate monitoring of therapeutic responses to cancer immunotherapies.

AB - Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities to overcome this challenge by refining tumor identification and monitoring therapeutic responses to cancer immunotherapy. In the current work, spatial and quantitative analysis of tumor burden were performed using simultaneous [18F]FDG-PET/MRI to monitor therapeutic responses to a novel silicified cancer cell immunotherapy in a mouse model of disseminated serous epithelial ovarian cancer. Tumor progression was validated by bioluminescence imaging of luciferase expressing tumor cells, flow cytometric analysis of immune cells in the tumor microenvironment, and histopathology. While PET demonstrated the presence of metabolically active cancer cells through [18F]FDG uptake, MRI confirmed cancer-related accumulation of ascites and tissue anatomy. This approach provides complementary information on disease status without a confounding signal from treatment-induced inflammation. This work provides a possible roadmap to facilitate accurate monitoring of therapeutic responses to cancer immunotherapies.

KW - MRI

KW - PET

KW - bioluminescence

KW - cancer vaccine

KW - cell silicification

KW - fluorodeoxyglucose

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85138349980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138349980&partnerID=8YFLogxK

U2 - 10.3390/ijms231810525

DO - 10.3390/ijms231810525

M3 - Article

C2 - 36142437

AN - SCOPUS:85138349980

VL - 23

JO - International journal of molecular sciences

JF - International journal of molecular sciences

SN - 1661-6596

IS - 18

M1 - 10525

ER -

Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this